---
title: "Telix appoints three new non-executive directors to expanded board"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293260571.md"
description: "Telix Pharmaceuticals Ltd. has appointed three new non-executive directors—David Gill, Maria Rivas, MD, and William Jellison—to its expanded board, effective May 11, 2026. The announcement was published by Telix on July 21, 2026."
datetime: "2026-07-20T22:48:14.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293260571.md)
  - [en](https://longbridge.com/en/news/293260571.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293260571.md)
---

# Telix appoints three new non-executive directors to expanded board

-   Telix appointed three non-executive directors, effective May 11, 2026: David Gill, Maria Rivas, MD, William Jellison. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on July 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here

### Related Stocks

- [TLX.US](https://longbridge.com/en/quote/TLX.US.md)
- [TLX.AU](https://longbridge.com/en/quote/TLX.AU.md)

## Related News & Research

- [Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer | TLX Stock News](https://longbridge.com/en/news/293255753.md)
- [Telix opens radiopharmaceutical facility in Australia for cancer treatment](https://longbridge.com/en/news/292888971.md)
- [Engie announces availability of H1 2026 interim financial report](https://longbridge.com/en/news/294468264.md)
- [FTRE: Q2 2026 saw improved profitability, higher guidance, and strong new business momentum](https://longbridge.com/en/news/294192218.md)
- [Medpace Exec VP Operations Susan Burwig disposes of 7,500 common shares for $4.5 million](https://longbridge.com/en/news/294257855.md)